Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Gemcitabine Hydrochloride in Renal Pelvis and Ureter Urothelial Carcinoma: NCT06822010 Clinical Landscape Report 2026
16 October 2026
NCT06822010 clinical landscape for Renal Pelvis and Ureter Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06827899 Clinical Landscape Report 2026
16 October 2026
NCT06827899 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cesnicabtagene Autoleucel in Plasma Cell Leukemia: NCT06830733 Clinical Landscape Report 2026
16 October 2026
NCT06830733 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nogapendekin alfa inbakicept-pmln in Non-Muscle Invasive Bladder Neoplasms: NCT06829823 Clinical Landscape Report 2026
16 October 2026
NCT06829823 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
BCG Live(Organon & Co.) in Carcinoma in Situ: NCT06833073 Clinical Landscape Report 2026
16 October 2026
NCT06833073 clinical landscape for Carcinoma in Situ: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Melphalan in Acute Myeloid Leukemia: NCT06829472 Clinical Landscape Report 2026
16 October 2026
NCT06829472 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Isatuximab-IRFC in Relapse multiple myeloma: NCT06832865 Clinical Landscape Report 2026
16 October 2026
NCT06832865 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Intrathecal Amniotic Fluid Stem Cells(Wake Forest School of Medicine) in Multiple Sclerosis, Chronic Progressive: NCT06841068 Clinical Landscape Report 2026
16 October 2026
NCT06841068 clinical landscape for Multiple Sclerosis, Chronic Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Ruxolitinib Phosphate in Dermatitis, Atopic: NCT06832618 Clinical Landscape Report 2026
16 October 2026
NCT06832618 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mesna in Myelofibrosis: NCT06834282 Clinical Landscape Report 2026
16 October 2026
NCT06834282 clinical landscape for Myelofibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Donor-derived CD123-CD16 bispecific antibody-modified NK cells(Chinese PLA General Hospital) in CD123 Positive Acute Myeloid Leukemia: NCT06835140 Clinical Landscape Report 2026
16 October 2026
NCT06835140 clinical landscape for CD123 Positive Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ocrelizumab Biosimilar in Multiple sclerosis relapse: NCT06847724 Clinical Landscape Report 2026
16 October 2026
NCT06847724 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.